Valion Bio: other events

Form 8-K filed Oct 26, 2026 · items 8.01

FDA decisionsValion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

What the filing says

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Valion Bio’s other material 8-Ks

Nov 5, 2026 — CFO changes
Nov 2, 2026 — FDA decisions NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome
Oct 29, 2026 — FDA decisions Valion Bio Announces Positive Safety Results from U.S. Government-Funded Entolimod Study, Paving Way
Oct 27, 2026 — Share offerings

Other recent fda decisions

Biovie Nov 6, 2026
Acrivon Therapeutics Nov 6, 2026
Entera Bio Nov 6, 2026
Precision Biosciences Nov 5, 2026
Sintx Technologies Nov 5, 2026
Microbot Medical Nov 5, 2026
Bioxytran Nov 5, 2026
Palvella Therapeutics Nov 5, 2026
ANI Pharmaceuticals Nov 5, 2026
Teleflex Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.